Get the Stockscreener App
244.98
3.42%
8.10
After Hours:
244.98
Bio Rad Laboratories Inc stock is traded at $244.98, with a volume of 215.06K.
It is up +3.42% in the last 24 hours and down -4.56% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$236.88
Open:
$240.82
24h Volume:
215.06K
Relative Volume:
0.65
Market Cap:
$6.86B
Revenue:
$2.58B
Net Income/Loss:
$-778.69M
P/E Ratio:
-8.9638
EPS:
-27.33
Net Cash Flow:
$223.75M
1W Performance:
+0.00%
1M Performance:
-4.56%
6M Performance:
-27.91%
1Y Performance:
-12.55%
1-Day Range:
$240.22
$245.87
1-Week Range:
$232.53
$248.67
52-Week Range:
$215.38
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
244.98 | 6.86B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
High Content Screening and Imaging Market Set for 8.4% CAGR Through 2029 - GlobeNewswire Inc.
Minimal Residual Disease Testing Market to Witness Massive - openPR.com
Microbiology Culture Market to Witness ~6% CAGR by 2030; with Top Key Players Merck KGaA; Bio-Rad Laboratories - PharmiWeb.com
Polymerase Chain Reaction Market Detailed In New Research - openPR.com
Hematology Analyzer Market Size to Reach $3.94 Billion by 2030 | - openPR.com
Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile? - Insider Monkey
Digital Pcr And Real-Time PCR Market Deep Research Report with - openPR.com
Should You be Optimistic on Bio-Rad Laboratories’s (BIO) Outlook? - Insider Monkey
Industrial Microbiology Market Set to Witness Significant - openPR.com
Cell-Free Protein Expression Market Projected To Witness - openPR.com
Fecal Calprotectin Test Market Overall Study Report 2025-2032 | - openPR.com
Surface Plasmon Resonance Market Is Booming Worldwide 2025-2032 | Bio-Rad Laboratories, Inc., Carterra Inc. - openPR.com
Drug Abuse Testing Market Forecast Report and Company Analysis 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad Labs, Medtronic - Yahoo Finance
Biochips Market Set to Witness Significant Growth by 2023 | - openPR.com
Biodetection Market Detailed In New Research Report 2025 | Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc. - openPR.com
Lobbying Update: $80,000 of BIO-RAD LABORATORIES lobbying was just disclosed - Nasdaq
Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - BioSpace
Bio-Rad to Report First Quarter 2025 Financial Results on Thursd - GuruFocus
Bio-Rad To Report First Quarter 2025 Financial Results On Thursday, May 1, 2025 - marketscreener.com
Bio-Rad Q1 2025 Earnings Release: Key Metrics and Growth Updates Coming May 1st - Stock Titan
Cancer Monoclonal Antibodies Market Projected To Witness - openPR.com
Sickle Cell Anemia Testing and Screening Market Detailed In New - openPR.com
Next Generation Sequencing (NGS) Market Growth, Trends & - openPR.com
Enzyme Linked Immunosorbent Assay Market Set for Significant - openPR.com
US Biomarkers Market worth $34.3 billion in 2029 - The Globe and Mail
Porphyria Treatment Market Detailed In New Research Report 2025 - openPR.com
Helicobacter Pylori Diagnostics Market Is Booming Worldwide | Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc. - openPR.com
Flow Cytometry Market Analysis: Trends, Growth, and Forecast - openPR.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Protein Assays Market Outlook: Growth Drivers and Future - openPR.com
Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)? - simplywall.st
Hemoglobinopathy Market Trends, Innovations, Growth & - openPR.com
Industrial Microbiology Market Future Business Opportunities - openPR.com
New Horizons in Microbiome Sample Preparation Technology - openPR.com
Polymerase Chain Reaction Market Projected To Witness - openPR.com
Enhancing Process Development with Viral Clearance: mAb Purification With a Weak AEX-HIC Chromatography Resin - BioProcess International
Clinical Biomarkers Market Key Players Analysis- QIAGEN, - openPR.com
RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating - marketscreener.com
Laboratory Supplies Market Projected To Witness Substantial - openPR.com
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
High End Cellomics Market Generated Opportunities, Future - openPR.com
Laboratory Proficiency Testing Market Deep Research 2025-2032 - openPR.com
Polyclonal Antibody Market Expansion | Drug Development & - openPR.com
Biodetection Market to Witness Stunning Growth with Bio-Rad - openPR.com
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):